Search for tag 'Fusies en overnames'

5 results Number of Results per Page
1
  1. Strong growth in Belgian mergers and acquisitions market

    2015 and the beginning of 2016 were characterised by a pronounced increase in the number of transactions in the Belgian mergers and acquisitions market. Demand is greater than supply, stimulated by easy and cheap access to finance and greater availability of financial resources to investment companies. Furthermore, the persistently low interest rate environment means there is increased interest from family investors, wealthy individuals and foreign private equity funds in Belgian medium-size enterprises. It is therefore not surprising that the prices paid are increasing across all sectors and business sizes. These are the findings from a survey of 142 Belgian mergers and acquisitions experts into their experiences over the past year.

  2. Closing the deal

    Why are some merger and acquisition (M&A) deals closed relatively quickly while others take much more time? The answer to this question is important, because prolonged deal duration is costly and postpones realising synergy gains.

  3. Case study

    Analysing deal structures in mergers and acquisitions: can you make the right match?

    Merger and Acquisitions (M&As) offer an interesting setting to analyse corporate financial decisions. These transactions might create a sudden need for additional external financial resources, leading to fundamental changes in a company’s capital structure. This case provides an overview of six M&A transactions with their unique features.

  4. Financial troubles? Have you considered an acquisition?

    While it is true that mergers and acquisitions have seen a moderate decline in the wake of the financial crisis, they continue to be important ways in which to grow or restructure businesses. Even though in the past it were primarily financially sound companies that took advantage of these techniques, nowadays an increasing number of acquisitions involve firms in financial troubles. Thorough academic analysis of such transactions is lacking, however. The research carried out by Evy Bruyland for her doctorate sets about filling this gap.

  5. Case study

    Big Pharma versus small biotech: analysing the financials of Pfizer and ImmunoCellular Therapeutics

    The continued consolidation in the pharmaceutical industry has baffled many individuals. Confronted with major threats like patent losses, a depressed economic environment, soaring R&D costs, low productive development pipelines, pricing pressure and generic competition, Big Pharma has struck multibillion dollar deals like the Pfizer - Wyeth acquisition in 2009. In this case, we contrast small biotech with Big Pharma.

1
5 results Number of Results per Page